First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.First-line chemotherapy improved overall survival in metastatic breast cancer with liver involvement compared to CDK4/6 inhibitors. Local therapies also enhanced survival, while larger lesions and endocrine resistance worsened outcomes.
Area Of Science
- Oncology
- Medical Research
- Clinical Trials
Background
- Metastatic breast cancer (HR+, HER2-) often presents with liver involvement, leading to poor prognosis.
- Optimal first-line treatment for this specific subgroup remains undetermined.
- Liver metastases in HR+, HER2- breast cancer require tailored therapeutic strategies.
Purpose Of The Study
- To compare the efficacy of first-line chemotherapy versus CDK4/6 inhibitors in HR+, HER2- metastatic breast cancer with liver involvement.
- To identify prognostic factors influencing survival outcomes in this patient population.
- To inform treatment decisions for patients with aggressive liver metastatic disease.
Main Methods
- Multicenter, retrospective study of 121 patients with HR+, HER2- metastatic breast cancer and liver lesions.
- Patients were categorized by first-line treatment: chemotherapy or CDK4/6 inhibitors (palbociclib, ribociclib).
- Cox regression analysis was used to determine independent prognostic factors for survival.
Main Results
- Progression-free survival was longer with CDK4/6 inhibitors (10.9 months) than chemotherapy (4.8 months).
- Overall survival was significantly improved with first-line chemotherapy (42.2 months) compared to CDK4/6 inhibitors (25.9 months).
- Local liver-directed therapies, hormonal status, and liver lesion size were independent predictors of survival.
Conclusions
- First-line chemotherapy demonstrated superior overall survival compared to CDK4/6 inhibitors in HR+, HER2- metastatic breast cancer with liver metastases.
- Local liver-directed therapies are associated with improved survival outcomes.
- Aggressive liver disease and endocrine resistance predict poorer survival, supporting chemotherapy consideration in select cases.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...